This Article Full Text Full Text (PDF) All Versions of this Article: j.jacc.2005.05.089v1 46/9/1628    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bittner, V. Search for Related Content PubMed PubMed Citation Articles by Bittner, V.

STATE-OF-THE-ART PAPER

Perspectives on Dyslipidemia and Coronary Heart Disease in Women

Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama

Manuscript received February 13, 2005; revised manuscript received April 20, 2005, accepted May 2, 2005.

^_* Reprint requests and correspondence: Dr. Vera Bittner, Division of Cardiovascular Disease, 701 19th Street South-LHRB 310, Birmingham, Alabama 35294-0007 (Email: vbittner{at}uab.edu).

Coronary heart disease (CHD) remains the leading cause of death among American women. Numerous differences exist between younger and older women and between women and men with respect to the pathology of CHD and its incidence and prevalence over the life cycle. Differences in lipoprotein levels and lipid fractions play an important role in CHD risk. Hormonal influences on lipoprotein levels in women are complex, change throughout the life span, and are influenced by the administration of oral contraceptives and hormone replacement therapy. Women with obesity, metabolic syndrome, or diabetes have lipid profiles that adversely affect CHD risk. To date, no randomized trials testing the impact of lifestyle changes on lipoprotein levels and subsequent CHD events in non-institutionalized women have been performed, and women have not been well represented in clinical end point trials of pharmacologic lipid-lowering therapy. Available evidence suggests that lipid-lowering therapy with statins does provide benefit in reducing the risk of coronary events in women; however, women remain undertreated, and more data are needed to determine optimal cardiovascular prevention and treatment in this population.

Abbreviations and Acronyms   ALLHAT = Antihypertensive and Lipid-Lowering Trial to Prevent Heart Attack   ATP III = Third Report of the Adult Treatment Panel   CHD = coronary heart disease   CVD = cardiovascular disease   HDL = high-density lipoprotein   HERS = Heart and Estrogen/progestin Replacement Study   LDL = low-density lipoprotein   Lp(a) = lipoprotein(a)   MI = myocardial infarction   RLP = remnant-like particle

This article has been cited by other articles:

				R. F. Zoeller Jr Lifestyle and the Risk of Cardiovascular Disease in Women: Is Physical Activity an Equal Opportunity Benefactor? American Journal of Lifestyle Medicine, June 1, 2008; 2(3): 219 - 226. [Abstract] [PDF]

				N K Wenger, S J Lewis, F K Welty, D M Herrington, V Bittner, and on behalf of the TNT Steering Committee and Invest Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study Heart, April 1, 2008; 94(4): 434 - 439. [Abstract] [Full Text] [PDF]

				H. M. Kim, J. Park, S. Y. Ryu, and J. Kim The Effect of Menopause on the Metabolic Syndrome Among Korean Women: The Korean National Health and Nutrition Examination Survey, 2001 Diabetes Care, March 1, 2007; 30(3): 701 - 706. [Abstract] [Full Text] [PDF]

				A. G. Rosenfeld State of the Heart: Building Science to Improve Women's Cardiovascular Health Am. J. Crit. Care., November 1, 2006; 15(6): 556 - 566. [Abstract] [Full Text] [PDF]

				R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., July 18, 2006; 48(2): 386 - 395. [Full Text] [PDF]